Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression

  • Nat Commun. 2022 Jul 6;13(1):3882. doi: 10.1038/s41467-022-31417-x.
Xinyuan Lei   #  1  2  3 Hsinyu Lin   #  1  3 Jieqi Wang   #  1  3 Zhanpeng Ou   #  1  3 Yi Ruan  1  3 Ananthan Sadagopan  4  5 Weixiong Chen  6 Shule Xie  1  3 Baisheng Chen  7 Qunxing Li  1  3 Jue Wang  8 Huayue Lin  3  9 Xiaofeng Zhu  3  9 Xiaoqing Yuan  3  9 Tian Tian  10 Xiaobin Lv  11  12 Sha Fu  8 Xiaorui Zhu  13 Jian Zhou  14 Guokai Pan  1  3 Xin Xia  1  3 Bakhos A Tannous  15 Soldano Ferrone  16 Song Fan  17  18 Jinsong Li  19  20
Affiliations
  • 1. Department of Oral and Maxillofacial Surgery, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, 510120, China.
  • 2. Molecular and Cellular Biology, State University of New York at Stony Brook, Stony Brook, NY, 11794, USA.
  • 3. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation of Sun Yat-Sen Memorial Hospital, Guangzhou, 510120, China.
  • 4. Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
  • 5. Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
  • 6. Department of Stomatology, Longgang District Central Hospital, Affiliated to Guangzhou University of Traditional Chinese Medicine, Shenzhen, 518116, China.
  • 7. Department of Thoracic Surgery, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, 510120, China.
  • 8. Cellular Molecular Diagnostics Center, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, 510120, China.
  • 9. Breast Tumor Center, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, 510120, China.
  • 10. Department of Neurobiology, Key Laboratory of Human Functional Genomics of Jiangsu, Nanjing Medical University, Nanjing, 211166, China.
  • 11. Nanchang Key Laboratory of Cancer Pathogenesis and Translational Research, Center Laboratory, the Third Affiliated Hospital, Nanchang University, Nanchang, 330047, China.
  • 12. Markey Cancer Center, the University of Kentucky, College of Medicine, Lexington, KY, 40506, USA.
  • 13. Department of Chronic Diseases Epidemiology, Yale University of Public Health, New Haven, CT, 06520, USA.
  • 14. Department of Medical Imaging, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.
  • 15. Experimental Therapeutics and Molecular Imaging Lab, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02129, USA.
  • 16. Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA. [email protected].
  • 17. Department of Oral and Maxillofacial Surgery, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, 510120, China. [email protected].
  • 18. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation of Sun Yat-Sen Memorial Hospital, Guangzhou, 510120, China. [email protected].
  • 19. Department of Oral and Maxillofacial Surgery, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, 510120, China. [email protected].
  • 20. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation of Sun Yat-Sen Memorial Hospital, Guangzhou, 510120, China. [email protected].
  • # Contributed equally.
Abstract

Mitochondrial dynamics can regulate Major Histocompatibility Complex (MHC)-I antigen expression by Cancer cells and their immunogenicity in mice and in patients with malignancies. A crucial role in the mitochondrial fragmentation connection with immunogenicity is played by the IRE1α-XBP-1s axis. XBP-1s is a transcription factor for Aminopeptidase TPP2, which inhibits MHC-I complex cell surface expression likely by degrading tumor antigen peptides. Mitochondrial fission inhibition with Mdivi-1 upregulates MHC-I expression on Cancer cells and enhances the efficacy of adoptive T cell therapy in patient-derived tumor models. Therefore mitochondrial fission inhibition might provide an approach to enhance the efficacy of T cell-based immunotherapy.

Products